Pharmaceutical Export Market in India 2021
Market insights:
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities. The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK. Pharmaceutical exports rose by 24.48% between FY 2020 and FY 2021 to reach INR 1,437.38 Bn in FY 2021. This was despite the global industry reduced by almost 2% in 2020 on account of COVID-19. As of 2021, nearly all medicines made domestically were low-cost generic drugs that comprise most of pharmaceutical export of the country.
Impact of COVID-19:
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country’s economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products. During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over INR 1,349 Bn worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.
Competitive insights:
Major players such as Sun Pharmaceuticals Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy’s Laboratories Limited have made huge strides in their net revenue. This is because of government initiatives that propelled export possibilities.
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities. The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK. Pharmaceutical exports rose by 24.48% between FY 2020 and FY 2021 to reach INR 1,437.38 Bn in FY 2021. This was despite the global industry reduced by almost 2% in 2020 on account of COVID-19. As of 2021, nearly all medicines made domestically were low-cost generic drugs that comprise most of pharmaceutical export of the country.
Impact of COVID-19:
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country’s economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products. During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over INR 1,349 Bn worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.
Competitive insights:
Major players such as Sun Pharmaceuticals Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy’s Laboratories Limited have made huge strides in their net revenue. This is because of government initiatives that propelled export possibilities.
CHAPTER 1: EXECUTIVE SUMMARY
CHAPTER 2: SOCIO-ECONOMIC INDICATORS
CHAPTER 3: INTRODUCTION
3.1. Market definition and structure
CHAPTER 4: MARKET OVERVIEW
4.1. Pharmaceutical export market in India – An overview
4.2. Export of pharmaceutical products (FY 2018 – FY 2021)
4.3. Country-wise export of pharmaceutical products (FY 2020 – FY 2021)
CHAPTER 5: COVID-19 IMPACT ASSESSMENT
5.1. Overview
5.1.1. Positive impact
5.1.2. Negative impact
5.2. Post-pandemic scenario
CHAPTER 6: TRADE ANALYSIS
6.1. Export of pharmaceutical products
6.1.1. Commodity-wise export – Based on value
6.1.2. Country-wise export – Based on value
6.1.3. Other exports – Based on value
CHAPTER 7: MARKET INFLUENCERS
7.1. Market drivers
7.2. Market challenges
CHAPTER 8: GOVERNMENT INITIATIVES
8.1 Government initiatives
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Sun Pharmaceuticals Industries Limited
Company information
Business description
Products/services
Key people
Financial snapshot
Key business segments
Key geographic segments
Note: Financial information covered only for public companies
9.2. Aurobindo Pharma Limited
9.3. Lupin Limited
9.4. Dr. Reddy’s Laboratories Limited
9.5. Cipla Limited
9.6. Cadila Healthcare Limited
9.7. Glenmark Pharmaceuticals Limited
9.8. Torrent Pharmaceuticals Limited
9.9. Alkem Laboratories Limited
9.10. Divi’s Laboratories Limited
CHAPTER 9: RECENT DEVELOPMENTS
9.1. Recent developments
CHAPTER 10: APPENDIX
10.1. Research methodology
10.2. About Netscribes
10.3. Disclaimer
COMPANIES PROFILED
Sun Pharmaceuticals Industries Limited
Aurobindo Pharma Limited
Lupin Limited
Dr. Reddy’s Laboratories Limited
Cipla Limited
Cadila Healthcare Limited
Glenmark Pharmaceuticals Limited
Torrent Pharmaceuticals Limited
Alkem Laboratories Limited
Divi’s Laboratories Limited
CHAPTER 2: SOCIO-ECONOMIC INDICATORS
CHAPTER 3: INTRODUCTION
3.1. Market definition and structure
CHAPTER 4: MARKET OVERVIEW
4.1. Pharmaceutical export market in India – An overview
4.2. Export of pharmaceutical products (FY 2018 – FY 2021)
4.3. Country-wise export of pharmaceutical products (FY 2020 – FY 2021)
CHAPTER 5: COVID-19 IMPACT ASSESSMENT
5.1. Overview
5.1.1. Positive impact
5.1.2. Negative impact
5.2. Post-pandemic scenario
CHAPTER 6: TRADE ANALYSIS
6.1. Export of pharmaceutical products
6.1.1. Commodity-wise export – Based on value
6.1.2. Country-wise export – Based on value
6.1.3. Other exports – Based on value
CHAPTER 7: MARKET INFLUENCERS
7.1. Market drivers
7.2. Market challenges
CHAPTER 8: GOVERNMENT INITIATIVES
8.1 Government initiatives
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Sun Pharmaceuticals Industries Limited
Company information
Business description
Products/services
Key people
Financial snapshot
Key business segments
Key geographic segments
Note: Financial information covered only for public companies
9.2. Aurobindo Pharma Limited
9.3. Lupin Limited
9.4. Dr. Reddy’s Laboratories Limited
9.5. Cipla Limited
9.6. Cadila Healthcare Limited
9.7. Glenmark Pharmaceuticals Limited
9.8. Torrent Pharmaceuticals Limited
9.9. Alkem Laboratories Limited
9.10. Divi’s Laboratories Limited
CHAPTER 9: RECENT DEVELOPMENTS
9.1. Recent developments
CHAPTER 10: APPENDIX
10.1. Research methodology
10.2. About Netscribes
10.3. Disclaimer
COMPANIES PROFILED
Sun Pharmaceuticals Industries Limited
Aurobindo Pharma Limited
Lupin Limited
Dr. Reddy’s Laboratories Limited
Cipla Limited
Cadila Healthcare Limited
Glenmark Pharmaceuticals Limited
Torrent Pharmaceuticals Limited
Alkem Laboratories Limited
Divi’s Laboratories Limited
